July 2025

Oncologists face burnout from administrative work, but new technology offers solutions to streamline workflows and improve patient care.

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their accessibility/safety.

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

During a live event, Deborah Wong, MD, PhD, discussed the role of EBV and challenges in nasopharyngeal cancer diagnosis with event participants.

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression after receiving pirtobrutinib for BTK inhibitor–pretreated chronic lymphocytic leukemia.

During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated chronic lymphocytic leukemia.

During a live event, Megan Kruse, MD, discussed sacituzumab govitecan's benefit, dosing, toxicity, and an ongoing earlier-line trial in metastatic breast cancer.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer.